| Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. | |
| | |
MedLine Citation:
|
PMID: 19507208 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Idiopathic thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease mediated by autoantibodies directed against ADAMTS-13. A number of small series and case reports have shown promising results with rituximab in refractory or relapsed TTP. In this report, we present 13 patients with TTP treated with rituximab. Twelve of the 13 patients (92%) achieved complete response; no subsequent relapses occurred with median follow-up of 24 months (range, 13-84 months). The addition of rituximab to standard therapy appears to be effective in sustaining long-term remission in TTP. However, the optimal dosing and timing of rituximab warrant further investigation. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc. |
| | |
Authors:
|
Huichung T Ling; Joshua J Field; Morey A Blinder |
Related Documents
:
|
12227878 - Successful treatment with doxycycline and nicotinamide of two cases of persistent pemph... 375278 - Primary iga glomerulonephritis and schönlein-henoch purpura nephritis: clinicopatholog... 6724078 - Alopecia areata: a clinical study. 1955678 - Intussusception associated with henoch-schonlein purpura. 7621208 - Closed reduction of a traumatically dislocated testicle. 21271598 - Causes of permanent childhood hearing impairment. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of hematology Volume: 84 ISSN: 1096-8652 ISO Abbreviation: Am. J. Hematol. Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-07-01 Completed Date: 2009-08-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7610369 Medline TA: Am J Hematol Country: United States |
Other Details:
|
Languages: eng Pagination: 418-21 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
ADAM Proteins
/
deficiency Adult Aged Antibodies, Monoclonal / therapeutic use* Antineoplastic Agents / therapeutic use* Female Follow-Up Studies Humans Male Middle Aged Purpura, Thrombotic Thrombocytopenic / blood, drug therapy* Remission Induction Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/rituximab; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.-/ADAMTS13 protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of external stimuli and cell micro-architecture on intracellular transport states.
Next Document: Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic m...